Diagnostic biomarker of asbestos-related mesothelioma: example of translational research

Hino Okio1, Shiomi Kazu, Maeda Masahiro

  • 1Department of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Tokyo, Japan. ohino@med.juntendo.ac.jp

Cancer Science
|May 30, 2007
PubMed

Insights

Asbestos exposure causes aggressive mesothelioma tumors with a 30-40 year incubation. Early diagnosis is crucial as effective treatments are lacking, highlighting the need for novel tumor markers.

Area of Science:

  • Environmental Health
  • Oncology
  • Toxicology

Background:

  • Mesothelioma is an aggressive cancer originating from the mesothelium.
  • It is strongly linked to prior asbestos exposure, with a long incubation period of 30-40 years.
  • Current treatments for mesothelioma are largely ineffective once the disease has developed.

Purpose of the Study:

  • To review the challenges and advancements in understanding asbestos-related mesothelioma.
  • To emphasize the urgent need for early diagnostic methods and tumor markers.
  • To present mesothelioma as a model for studying environmental carcinogenesis.

Main Methods:

  • Review of existing literature on mesothelioma and asbestos exposure.
  • Discussion of diagnostic tools, specifically enzyme-linked immunosorbent assay (ELISA) systems for Erc/mesothelin.
  • Analysis of mesothelioma as an environmental carcinogen.

Main Results:

  • Asbestos is a significant environmental carcinogen causing mesothelioma.
  • Enzyme-linked immunosorbent assay (ELISA) systems for Erc/mesothelin show promise as diagnostic tools.
  • Early detection methods are critical due to the lack of effective treatments.

Conclusions:

  • Mesothelioma, often caused by asbestos, necessitates urgent development of early diagnostic markers.
  • Erc/mesothelin shows potential as a diagnostic marker for mesothelioma.
  • Studying asbestos-related mesothelioma offers insights into environmental carcinogenesis.

Related Concept Videos